Ali Rabie - Energy Engineering and Physics Department, Amirkabir University of Technology, Tehran, Iran
Hassan Yousefnia - Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
Samaneh Zolghadri - Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
Mojtaba Shamsaei - Energy Engineering and Physics Department, Amirkabir University of Technology, Tehran, Iran

Introduction: Bone metastases are common in the progression of various tumors leading to severe pain and decrease in quality of life. The aim of this study was to optimize the production of 68Ga-BPAMD as an ideal bone imaging agent using an in-house 68Ge/68Ga generator for future clinical use. Methods: The optimized conditions for the preparation of 68Ga-BPAMD were determined by varying ligand concentration, pH, time and temperature. The radiochemical purity of the complex was checked using ITLC method. The stability at room temperature and in human serum and the hydroxyapatite (HA) binding of the complex were studied. Biodistribution of 68Ga-BPAMD and 68GaCl3 were investigated in male Syrian rats. Results:The radiolabelled compound was prepared with a radiochemical purity of > 99% after 15 min at the optimized conditions (30 µg of ligand, 90 °C, pH=3-5). The complex was stable in the final preparation and in the presence of human serum (> 98%). HA binding assay demonstrated that at the amount of 10 and 25 mg of HA, 62.3 and 88.5 % of the complex are bound to HA, respectively. The agent demonstrated significant accumulation in the bone tissue, while cleared very fast from blood circulation. Major difference in uptake between 68Ga-BPAMD and 68GaCl3 was observed especially in blood, bone, liver, and spleen which can be considered as favorable characteristics of this agent. Conclusion: According to these results, this agent can be produced with the recently developed in-house generator and considered as a worthy bone PET imaging agent available for further clinical use.

Bone metastasis, BPAMD, 68Ga, PET scan